Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Sponsor: Women's Hospital School Of Medicine Zhejiang University
Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Official title: Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2025-03-10
Completion Date
2029-12-31
Last Updated
2025-12-18
Healthy Volunteers
No
Conditions
Interventions
Camrelizumab combined with chemotherapy
Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Locations (1)
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China